Peptic Gastritis – A Complete Patient Guide

Overview

Peptic gastritis (often simply called gastritis) is inflammation of the stomach lining (the gastric mucosa). When the inflammation involves the portion of the stomach that secretes acid and digestive enzymes, it is sometimes referred to as “peptic” gastritis. The condition can be acute (sudden onset, lasting days to weeks) or chronic (persistent, lasting months or years).

• Who it affects: Adults of any age, but it is most common in people aged 30‑60. Women are slightly more likely to be diagnosed than men (≈55 % vs. 45 %).
• Prevalence: Worldwide, gastritis affects an estimated 5‑10 % of the adult population; in the United States, about 1.3 million outpatient visits are coded for gastritis each year ¹. Chronic gastritis is especially prevalent in regions with higher rates of Helicobacter pylori infection.

Symptoms

Symptoms can be mild and intermittent or severe enough to interfere with daily life. Not everyone with gastritis experiences every symptom.

Common Symptoms

• Upper abdominal pain or discomfort – often described as gnawing, burning, or a “bunch of nerves” feeling. Pain may improve or worsen after eating.
• Epigastric fullness or bloating – a sensation of swelling in the upper stomach.
• Nausea and occasional vomiting – vomit may contain undigested food or, rarely, blood.
• Loss of appetite – leading to unintended weight loss.
• Belching and excessive gas.

Less Common / Alarming Symptoms

• Dark, tar‑like stools (melena) – a sign of upper‑GI bleeding.
• Vomiting bright red blood (hematemesis).
• Unexplained iron‑deficiency anemia.
• Severe, unrelenting abdominal pain that wakes you from sleep.

Causes and Risk Factors

Gastric inflammation results from direct injury to the mucosal barrier or from impaired healing. The most frequent causes include:

Infectious

• Helicobacter pylori infection – responsible for ~50‑70 % of chronic gastritis cases worldwide ².
• Viral infections (e.g., cytomegalovirus, herpes simplex) in immunocompromised patients.

Medication‑Related

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – ibuprofen, naproxen, aspirin, and selective COX‑2 inhibitors.
• Low‑dose aspirin used for cardiovascular protection.
• Other ulcerogenic drugs: corticosteroids, potassium chloride tablets.

Other Causes

• Excessive alcohol consumption (≥ 3 drinks/day for men, ≥ 2 drinks/day for women).
• Autoimmune gastritis – antibodies attack parietal cells, leading to mucosal damage.
• Stress‑related mucosal injury (“stress gastritis”) seen in severe trauma, burns, or ICU patients.
• Reflux of bile or duodenal contents into the stomach.

Risk Factors

• Age > 60 years (declining mucosal protection).
• Smoking – impairs mucosal blood flow and healing.
• Chronic use of NSAIDs or aspirin.
• Heavy alcohol use.
• History of peptic ulcer disease.
• Living in regions with high H. pylori prevalence (e.g., parts of Asia, Africa, Latin America).

Diagnosis

Because many gastrointestinal complaints overlap, a systematic approach is required.

Clinical Evaluation

• Detailed medical history – medication use, alcohol intake, prior infections.
• Physical examination – checking for tenderness, signs of anemia, or abdominal masses.

Laboratory Tests

• Complete blood count (CBC) – detects anemia or infection.
• Serum gastrin (in rare cases of autoimmune gastritis).
• H. pylori testing:
  • Urea breath test (non‑invasive, > 95 % sensitivity).
  • Stool antigen test.
  • Serologic IgG antibodies (less specific).

Endoscopic Evaluation (Upper GI Endoscopy)

Considered the gold standard when:

• Symptoms persist > 4 weeks despite empirical therapy.
• Alarm features are present (bleeding, weight loss, anemia).
• Patients are > 60 years old with new‑onset dyspepsia.

During endoscopy, the doctor can visually grade inflammation, obtain biopsies for histology, and test biopsied tissue for H. pylori (rapid urease test, histology, culture).

Imaging (Rarely Needed)

• Abdominal ultrasound or CT scan – only if complications such as perforation are suspected.

Treatment Options

Treatment aims to eliminate the underlying cause, reduce acid irritation, and promote mucosal healing.

Medications

• Proton‑pump inhibitors (PPIs) – omeprazole, esomeprazole, lansoprazole. Reduce gastric acid secretion and are first‑line for both acute and chronic gastritis.
• H2‑receptor antagonists – ranitidine (withdrawn in many countries), famotidine, cimetidine. Useful as step‑down therapy after symptom control.
• Antacids – calcium carbonate, magnesium hydroxide – offer rapid short‑term relief.
• H. pylori eradication regimen – typically a 14‑day triple therapy (PPI + clarithromycin + amoxicillin or metronidazole) or a 10‑day bismuth‑based quadruple therapy. Follow‑up testing ensures eradication.
• Protective agents – sucralfate (coats the mucosa) or misoprostol (prostanoid analog) in NSAID‑induced gastritis.
• Antibiotics for bacterial overgrowth – when indicated.

Procedural Interventions

• Endoscopic hemostasis – clips, thermal coagulation, or injection therapy for active bleeding.
• Endoscopic dilation – rarely needed if chronic inflammation leads to gastric outlet obstruction.

Lifestyle & Dietary Adjustments

• Eliminate or reduce NSAIDs and aspirin; use COX‑2–selective agents only under physician guidance.
• Limit alcohol to ≤ 1 drink/day for women and ≤ 2 drinks/day for men.
• Quit smoking – nicotine impairs mucosal blood flow.
• Adopt a “gentle” diet:
  • Small, frequent meals.
  • Avoid spicy, fried, or highly acidic foods (citrus, tomato‑based sauces).
  • Incorporate bland proteins (lean poultry, fish), cooked vegetables, and whole grains.
  • Stay upright for at least 30 minutes after eating.
• Stress‑reduction techniques (mindfulness, yoga, regular exercise) can improve symptom perception.

Living with Peptic Gastritis

Effective self‑management reduces flare‑ups and improves quality of life.

Daily Management Tips

• Medication adherence – take PPIs 30 minutes before breakfast; never skip doses.
• Food diary – track meals, symptoms, and triggers to identify personal irritants.
• Hydration – sip water throughout the day; avoid carbonated or caffeinated beverages that may increase acid production.
• Weight maintenance – undernutrition can impair healing; aim for a balanced caloric intake.
• Regular follow‑up – repeat endoscopy or H. pylori testing as recommended (usually 4‑6 weeks after therapy).

When to Adjust Treatment

If symptoms persist after 4–8 weeks of optimal therapy, return to your clinician for reassessment—possible reasons include antibiotic resistance, missed medication, or an alternative diagnosis such as peptic ulcer disease or gastric cancer.

Prevention

Preventive measures focus on protecting the gastric mucosa and limiting exposure to known irritants.

• Use NSAIDs sparingly – take with food, consider intermittent dosing, or switch to acetaminophen when appropriate.
• Test and treat H. pylori in high‑risk populations (e.g., those with a family history of gastric cancer or chronic gastritis).
• Vaccinate against hepatitis B – chronic liver disease can exacerbate gastritis.
• Maintain a healthy weight – obesity is linked to increased gastric inflammation.
• Stress management – regular physical activity, adequate sleep, and relaxation practices.
• Limit or avoid tobacco and alcohol – both directly damage the gastric lining.

Complications

When left untreated or poorly controlled, peptic gastritis can lead to serious outcomes.

• Peptic ulcer disease – erosion deepens into the muscular layer, causing pain and risk of bleeding.
• Upper gastrointestinal bleeding – may present as melena or hematemesis; can be life‑threatening.
• Gastric outlet obstruction – chronic inflammation and scarring narrow the pylorus.
• Atrophic gastritis & intestinal metaplasia – precursor lesions for gastric adenocarcinoma, particularly in H. pylori‑associated chronic gastritis.
• Iron‑deficiency anemia – from chronic blood loss or impaired iron absorption.

When to Seek Emergency Care

---

Sources:
1. Centers for Disease Control and Prevention (CDC). “Gastrointestinal Diseases – Outpatient Visits.” 2022.
2. World Health Organization (WHO). “Helicobacter pylori in Gastric Cancer.” 2021.
Mayo Clinic. “Gastritis.” Updated 2023.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Peptic Ulcer and Gastritis.” 2022.
Cleveland Clinic. “Treatment of H. pylori Infection.” 2023.